4,482 followers
@SteveMaronMD @KlempnerSam Thought OSi data was with Necitumumab in NSCLC- https://t.co/WdcKU7N2A9
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.
Overview of attention for article published in Journal of Clinical Oncology, May 2019